MaximBio Announces Key Appointments to Board of Directors and Board of Advisors
Rockville, MD – Maxim Biomedical, a leading innovator in diagnostic testing solutions, proudly announces the addition ofTheresa Tribble to its Board of Directors and the appointment of Doug Bryantand Mike Abney to its Board of Advisors. These highly respected leaders bring leading expertise in life sciences, diagnostics, and healthcare innovation, positioning MaximBio to further advance its mission of improving health outcomes worldwide.
Doug Bryant, renowned for his transformative leadership as CEO of Quidel Corporation (later QuidelOrtho), joins MaximBio's Board of Advisors. Over his 15 years at Quidel, Mr. Bryant oversaw groundbreaking achievements, including growing the business from approximately $150m to approximately $3b of revenue, its critical role in global pandemic response efforts, and its 2022 merger with Ortho Clinical Diagnostics to builda global diagnostic leader.
Theresa Tribble, brings two decades of experience scaling innovative diagnostic companies to the Board of Directors. Ms. Tribble formerly served as CEO of Droplet Biosciences, Operating Partner at The Engine, and as the first Chief Business Officer of Everlywell (now Everly Health), the leading at-home testing provider. While at Everlywell, Ms. Tribble led all non-Everlywell.com verticals, including brick-and-mortar and online retail distribution.
Mike Abney, with extensive diagnostic industry knowledge and a focus on building and scaling commercial excellence, joins the Board of Advisors. Previously, Mr. Abney served as Senior Vice President, North American Sales & Distribution at Quidel Corporation. Prior to joining Quidel, he served in executive roles in manufacturing and distribution including as Vice President at PSS WorldMedical.
“We are excited to welcome Doug, Theresa, and Mike to Maxim Biomedical,” said Jonathan Maa, CEO of Maxim Biomedical. “Doug’s unparalleled leadership and history of growth, Theresa’s entrepreneurial acumen, and Mike’s insight into building and scaling the go-to-market at the highest levels further positions Maxim to deliver even greater value to our partners and customers.”
About Maxim Biomedical
Maxim Biomedical, based in Rockville, Maryland, is a leader in the developmentand manufacturing of in vitro diagnostic (IVD) solutions with expertise inlateral flow assays and ELISA technologies. As a trusted partner to healthcareorganizations worldwide, MaximBio provides comprehensive development andmanufacturing services, from initial concept to large-scale production. At Maxim Biomedical, our mission is to advance global health outcomes through high-quality, accessible, and innovative diagnostic solutions. For more information about Maxim Biomedical, visit www.maximbio.com.